FIG 3.

Rate of response to immune checkpoint inhibitors by tumor mutational burden (TMB) threshold. (A) Rate of durable clinical benefit (DCB) increases with increasing TMB cutoff thresholds. TMB z score deciles were selected as cut points, and rate of DCB was calculated for patients in the joint cohorts whose TMB z scores were greater than or equal to the cut point. Bars depict rate of DCB. The leftmost bar depicts rate of DCB in the unselected cohort (TMB ≥ 0th percentile). (B) The rate of DCB within TMB z score deciles is more variable. Bars depict rate of DCB among patients whose TMB z scores are greater than or equal to the lower bound and less than the upper bound. (C) The odds ratio of DCB varies with increasing TMB z score cut points. Bars depict odds ratio; significant P values are indicated above bars. (D) Receiver operating characteristic curve demonstrates a trade-off in sensitivity v specificity of DCB at varying TMB z score values. Exploratory cut points, with their associated specificity and sensitivity, are indicated. Error bars represent standard error. Numbers over bar graphs indicate number of patients in each group. (*) P < .05, (†) P < .01, (‡) P < .001. AUC, area under the curve.